A bone marrow transplant (BMT), also called a Hematopoietic Stem Cell Transplant, is a procedure that replaces diseased or damaged bone marrow with healthy stem cells. These stem cells are the "factories" that produce your red blood cells, white blood cells, and platelets.
To replace non-functioning marrow in conditions such as Aplastic Anemia.
To "rescue" the marrow after high-dose chemotherapy for Leukemia, Lymphoma, or Multiple Myeloma.
To replace "broken" or genetically abnormal cells in disorders like Sickle Cell Disease or Thalassemia.
When other primary treatments have failed and a transplant offers the only curative option.
Following the identification of a matched donor or the successful collection of own healthy stem cells.
Autologous Transplant: A procedure using the patient's own stem cells, which are collected and frozen before intensive treatment.
Allogeneic Transplant: A transplant using stem cells from a matched relative or an unrelated volunteer donor.
Matched Sibling Donor: Using a brother or sister who has the same human leukocyte antigen (HLA) type.
Haploidentical Transplant: A type of allogeneic transplant using a donor who is a "half-match," such as a parent or child.
Umbilical Cord Blood Transplant: Using stem cells harvested from the umbilical cord and placenta after a baby is born.
Conditioning: Administration of high-dose chemotherapy or radiation over 5–7 days to clear out old marrow.
Stem Cell Infusion: Healthy cells are infused through a central venous catheter (PICC or Hickman line), similar to a blood transfusion.
Engraftment: A 2–4 week period where the new cells travel to the bones and begin producing new blood cells.
Immune Reset: The process of the new immune system gradually maturing and learning to protect the body.
Continuous Monitoring: Intensive observation in the hospital to manage the high risk of infection during the recovery phase.
Extensive work-up testing of the heart, lungs, and kidneys to ensure the body can handle the procedure.
Placement of a central venous catheter for the infusion of cells and administration of medications.
Coordination of stem cell collection (apheresis) for autologous patients or donor matching for allogeneic patients.
Understanding the "Point of No Return" during the conditioning phase where the old marrow is destroyed.
HLA Typing: A specialized blood test used to match patients with the most compatible donors.
Bone Marrow Biopsy: To assess the current state of the marrow and the presence of any remaining cancer cells.
Organ Function Screens: Detailed evaluations including ECGs, lung function tests, and kidney filtration checks.
Infectious Disease Screening: Comprehensive testing for viruses or bacteria that could become dangerous during recovery.
Most patients remain hospitalized for 3–5 weeks following the infusion.
Long-term recovery is a gradual process requiring close medical supervision for up to a year.
Patients must follow strict infection-prevention protocols while their immune system is "reset" to zero.
Ongoing management may include anti-rejection medications to prevent Graft-vs-Host Disease (GVHD).
Provides a curative pathway for many blood cancers that are resistant to standard chemotherapy.
Restores the body's ability to produce healthy, functional red blood cells, white blood cells, and platelets.
Corrects the underlying genetic "blueprints" in patients with hereditary blood disorders.
Offers a chance for long-term remission and the restoration of a healthy immune system.
